UB Paderborn / Katalog / Suche / in CDI

1 – 23 von 23

Sortiert nach

The atypical chemokine receptor ACKR3/CXCR7 is a broad-spectrum scavenger for opioid peptides

Nature communications, 2020-06, Vol.11 (1), p.3033-3033, Article 3033

2020

Volltextzugriff (PDF)

Systematic reassessment of chemokine‐receptor pairings confirms CCL20 but not CXCL13 and extends the spectrum of ACKR4 agonists to CCL22

Journal of leukocyte biology, 2021-02, Vol.109 (2), p.373-376

2021

Volltextzugriff (PDF)

A Novel ACKR2-Dependent Role of Fibroblast-Derived CXCL14 in Epithelial-to-Mesenchymal Transition and Metastasis of Breast Cancer

Clinical cancer research, 2019-06, Vol.25 (12), p.3702-3717

2019

Volltextzugriff (PDF)

Mutational analysis of the extracellular disulphide bridges of the atypical chemokine receptor ACKR3/CXCR7 uncovers multiple binding and activation modes for its chemokine and endogenous non-chemokine agonists

Biochemical pharmacology, 2018-07, Vol.153, p.299-309

2018

Volltextzugriff (PDF)

The diverse and complex roles of atypical chemokine receptors in cancer: From molecular biology to clinical relevance and therapy

Advances in cancer research, 2020, Vol.145, p.99-138

2020

Volltextzugriff (PDF)

Assessment of Biased Agonism among Distinct Synthetic Cannabinoid Receptor Agonist Scaffolds

ACS pharmacology & translational science, 2020-04, Vol.3 (2), p.285-295

2020

Volltextzugriff (PDF)

CXCL10 Is an Agonist of the CC Family Chemokine Scavenger Receptor ACKR2/D6

Cancers, 2021-03, Vol.13 (5), p.1054

2021

Volltextzugriff (PDF)

The natural analgesic conolidine targets the newly identified opioid scavenger ACKR3/CXCR7

Signal transduction and targeted therapy, 2021-06, Vol.6 (1), p.209-209, Article 209

2021

Volltextzugriff (PDF)

CXCL14 Preferentially Synergizes With Homeostatic Chemokine Receptor Systems

Frontiers in immunology, 2020-10, Vol.11, p.561404-561404

2020

Volltextzugriff (PDF)

The Extended N-Terminal Domain Confers Atypical Chemokine Receptor Properties to CXCR3-B

Frontiers in immunology, 2022-06, Vol.13, p.868579-868579

2022

Volltextzugriff (PDF)

The soluble form of pan-RTK inhibitor and tumor suppressor LRIG1 mediates downregulation of AXL through direct protein-protein interaction in glioblastoma

Neuro-oncology advances, 2019-05, Vol.1 (1), p.vdz024-vdz024

2019

Volltextzugriff (PDF)

Atypical opioid receptors: unconventional biology and therapeutic opportunities

Pharmacology & therapeutics (Oxford), 2022-05, Vol.233, p.108014-108014, Article 108014

2022

Volltextzugriff (PDF)

Characterization of a Threonine-Rich Cluster in Hepatitis C Virus Nonstructural Protein 5A and Its Contribution to Hyperphosphorylation

Journal of virology, 2018-12, Vol.92 (24)

2018

Volltextzugriff (PDF)

Different contributions of chemokine N‐terminal features attest to a different ligand binding mode and a bias towards activation of ACKR3/CXCR7 compared with CXCR4 and CXCR3

British journal of pharmacology, 2018-05, Vol.175 (9), p.1419-1438

2018

Volltextzugriff (PDF)

Multiple Drugs Compete for Transport via the Plasmodium falciparum Chloroquine Resistance Transporter at Distinct but Interdependent Sites

The Journal of biological chemistry, 2014-12, Vol.289 (52), p.36336-36351

2014

Volltextzugriff (PDF)

Nanoluciferase-based cell fusion assay for rapid and high-throughput assessment of SARS-CoV-2-neutralizing antibodies in patient samples

Methods in enzymology, 2022, Vol.675, p.351-381

2022

Volltextzugriff (PDF)

Proadrenomedullin N‑Terminal 20 Peptides (PAMPs) Are Agonists of the Chemokine Scavenger Receptor ACKR3/CXCR7

ACS pharmacology & translational science, 2021-04, Vol.4 (2), p.813-823

2021

Volltextzugriff (PDF)

Creation of a pandemic memory by tracing COVID-19 infections and immunity in Luxembourg (CON-VINCE)

BMC infectious diseases, 2024-02, Vol.24 (1), p.179-179, Article 179

2024

Volltextzugriff (PDF)

Nanoluciferase-based complementation assays to monitor activation, modulation and signaling of receptor tyrosine kinases (RTKs)

Methods in enzymology, 2023, Vol.682, p.1-16

2023

Volltextzugriff (PDF)

Nanoluciferase-based complementation assay for systematic profiling of GPCR–GRK interactions

Biomolecular Interactions Part B, 2022, Vol.169, p.309-321

2022

Volltextzugriff (PDF)

Nanoluciferase-based methods to monitor activation, modulation and trafficking of atypical chemokine receptors

Biomolecular Interactions Part B, 2022, Vol.169, p.279-294

2022

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(17)

Publikationsform

Sprache

Englisch
(23)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(21)
Life Sciences & Biomedicine
(20)
Humans
(10)
Life Sciences
(10)
Sciences Du Vivant
(10)
Biochemistry, Biophysics & Molecular Biology
(9)
Biochimie, Biophysique & Biologie Moléculaire
(9)
Biochemistry & Molecular Biology
(7)
Ackr3
(6)
Chemokines
(5)
Ligands
(5)
Pharmacology & Pharmacy
(5)
Signal Transduction
(5)
Ackr2
(4)
Beta-Arrestins - Metabolism
(4)
Cell Biology
(4)
Oncology
(4)
Animals
(3)
Arrestin
(3)
Biochemical Research Methods
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The atypical chemokine receptor ACKR3/CXCR7 is a broad-spectrum scavenger for opioid peptides

Systematic reassessment of chemokine‐receptor pairings confirms CCL20 but not CXCL13 and extends the spectrum of ACKR4 agonists to CCL22

A Novel ACKR2-Dependent Role of Fibroblast-Derived CXCL14 in Epithelial-to-Mesenchymal Transition and Metastasis of Breast Cancer

Mutational analysis of the extracellular disulphide bridges of the atypical chemokine receptor ACKR3/CXCR7 uncovers multiple binding and activation modes for its chemokine and endogenous non-chemokine agonists

The diverse and complex roles of atypical chemokine receptors in cancer: From molecular biology to clinical relevance and therapy

Assessment of Biased Agonism among Distinct Synthetic Cannabinoid Receptor Agonist Scaffolds

CXCL10 Is an Agonist of the CC Family Chemokine Scavenger Receptor ACKR2/D6

The natural analgesic conolidine targets the newly identified opioid scavenger ACKR3/CXCR7

CXCL14 Preferentially Synergizes With Homeostatic Chemokine Receptor Systems

The Extended N-Terminal Domain Confers Atypical Chemokine Receptor Properties to CXCR3-B

The soluble form of pan-RTK inhibitor and tumor suppressor LRIG1 mediates downregulation of AXL through direct protein-protein interaction in glioblastoma

Atypical opioid receptors: unconventional biology and therapeutic opportunities

Characterization of a Threonine-Rich Cluster in Hepatitis C Virus Nonstructural Protein 5A and Its Contribution to Hyperphosphorylation

Different contributions of chemokine N‐terminal features attest to a different ligand binding mode and a bias towards activation of ACKR3/CXCR7 compared with CXCR4 and CXCR3

Pharmacological Characterization and Radiolabeling of VUF15485, a High-Affinity Small-Molecule Agonist for the Atypical Chemokine Receptor ACKR3

Multiple Drugs Compete for Transport via the Plasmodium falciparum Chloroquine Resistance Transporter at Distinct but Interdependent Sites

Nanoluciferase-based cell fusion assay for rapid and high-throughput assessment of SARS-CoV-2-neutralizing antibodies in patient samples

Proadrenomedullin N‑Terminal 20 Peptides (PAMPs) Are Agonists of the Chemokine Scavenger Receptor ACKR3/CXCR7

Creation of a pandemic memory by tracing COVID-19 infections and immunity in Luxembourg (CON-VINCE)

Nanoluciferase-based complementation assays to monitor activation, modulation and signaling of receptor tyrosine kinases (RTKs)

Nanoluciferase-based complementation assay for systematic profiling of GPCR–GRK interactions

Nanoluciferase-based methods to monitor activation, modulation and trafficking of atypical chemokine receptors

Different contribution of chemokine N-terminal features attest a different ligand binding mode and a bias towards activation of the atypical chemokine receptor ACKR3/CXCR7 compared to CXCR4 and CXCR3

Suchergebnisse filtern